What is the mainstay of antiplatelet therapy for patients with non ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS)?
Aspirin is the established first-line therapy in patients with NSTE-ACS and reduces the incidence of recurrent MI and A loading dose of non enteric-coated aspirin 162 mg to 325 mg is the initial antiplatelet therapy.